Search the Newsreel

Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss

Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …

Xenetic partner receives Israeli approvals for lymphoma study

Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …

SOPHiA GENETICS (SOPH) insider plans Rule 144 sale after 10b5-1 trades

SOPHiA GENETICS (SOPH) has filed a Form 144 indicating a proposed sale of 20,000 common shares with an aggregate market value of $133,800.00, anticipated on August 7, 2026. This filing also details previous Rule 10b5-1 plan sales by Jurgi Camblong, including significant transactions on …

Prenetics (Nasdaq: PRE) files F-1 to register 2.36M warrant shares for resale

Prenetics Global Limited (Nasdaq: PRE) has filed an F-1 registration statement to allow for the resale of up to 2.36 million Class A Ordinary Shares by existing holders of Class C "Exchange Warrants." The company will not receive proceeds from the resales but may …

Noticias de acciones de Fulgent Genetics Inc (FLGT)

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discuss your legal rights, contact Bragar Eagel …

Here’s How Much You Would Have Made Owning Tenet Healthcare Stock In The Last 15 Years

Tenet Healthcare (NYSE: THC) has outperformed the market over the past 15 years with an average annual return of 18.6%. An initial investment of $100 in THC stock 15 years ago would now be worth $1,323.89, demonstrating the power of compounded returns. The company …

Myriad Genetics Inc (MYD.HA) stock price, news, quote and history

Fulgent Genetics, Inc. (FLGT) Stock Price, News, Quote & History

This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering …

State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics

State Street Corporation has disclosed a 5.3% beneficial ownership in Myriad Genetics, Inc. (MYGN), amounting to 4,985,060 shares. This ownership is managed through various asset management subsidiaries, with shared voting and dispositive power over the shares. The filing, a SCHEDULE 13G, indicates a passive …

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) after the company reported Q2 2026 revenues below Wall Street expectations and significantly cut its full-year 2026 revenue guidance. The firm encourages stockholders to contact them to learn more about the investigation into …

Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk

Prenetics to Stream Q2 Results on Stocktwits Aug. 18

Tenet Hires Experienced Sales Manager to Help with Business Hub Expansion

Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Tenet Fintech Group Inc. (CSE: PKK) (OTC Pink: PKKFF) ("Tenet" or the "Company"), an innovative analytics service provider, owner and operator of the Cubeler Business Hub, today announced that experienced sales manager Warren Haughton has joined …

Tenet Healthcare (NYSE:THC): Undervalued With Strong Profitability

Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company continued to advance (Z)-endoxifen for rare pediatric diseases like Duchenne Muscular Dystrophy and McCune-Albright Syndrome, and for breast cancer, supported by new data …

Xenetic Biosciences: Q2 Earnings Snapshot

Atossa Genetics (ATOS) Earnings Date and Reports 2026 $ATOS

Opus Genetics (NASDAQ:IRD) Releases Earnings Results

Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary

Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily …

Karmanos Cancer Hospital sues Detroit Medical Center over threats to patient care services

Karmanos Cancer Hospital is suing Detroit Medical Center (DMC) and its parent company Tenet, alleging threats to terminate or reduce essential patient care services. Karmanos claims DMC has restricted its expansion efforts and implemented unjustified cost increases for support services, transforming a business disagreement …

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Myriad Genetics, Inc. (MYGN) after the company reported significantly lower-than-expected Q2 2026 revenue and drastically cut its full-year 2026 guidance. This announcement followed Myriad Genetics reiterating stronger guidance just three months prior, leading …

FMR LLC (THC) reports 3.99M-share, 4.6% Tenet Healthcare stake in 13G/A

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, reporting a beneficial ownership stake of 3,994,545.39 shares in Tenet Healthcare Corp (THC), which represents 4.6% of the common stock outstanding. FMR LLC holds sole dispositive power over all these shares and …

HC Wainwright Predicts Reduced Earnings for SOPHiA GENETICS

HC Wainwright has lowered its FY2029 earnings per share forecast for SOPHiA GENETICS (NASDAQ: SOPH) to $0.31 from $0.34, while maintaining a Buy rating and a $14 price target. The company recently reported a quarterly loss of $0.26 per share, missing consensus estimates, despite …

McLaren sues DMC over Karmanos contract dispute

McLaren Health Care has filed a lawsuit against Detroit Medical Center (DMC) and Tenet Healthcare over a contract dispute concerning the Karmanos Cancer Institute. The lawsuit was filed on August 6, 2026, and seeks to resolve issues related to their agreement. Karmanos Cancer Institute …

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Tenet Healthcare's (NYSE:THC) Earnings Are Of Questionable Quality

Tenet Healthcare recently reported strong earnings, but an analysis suggests that investors might be overlooking details beneath the profit numbers. The company's statutory profit was significantly boosted by US$313 million in unusual items, which are typically one-off occurrences. This raises concerns about the sustainability …

SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 10,000 Shares

SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of the company's stock on August 4th, reducing their position by 1.64%. The transaction, valued at $69,200, was conducted under a pre-arranged Rule 10b5-1 plan. Despite the insider sale and a recent stock dip, analysts …

SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics

SOPHiA GENETICS has announced a multi-year global partnership with AstraZeneca to develop and launch two companion diagnostics for precision oncology therapies. This collaboration aims to create decentralised clinical trial assays and diagnostic solutions for both solid tumors and blood cancers. The goal is to …

Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have …

SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $138,400.00 in Stock

SOPHiA GENETICS Chairman Jurgi Camblong sold 20,000 shares of the company's stock for $138,400 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 0.57%. This insider sale comes amidst mixed quarterly results where revenue exceeded expectations but the company reported a larger-than-anticipated loss …

TENET HEALTHCARE CORP SEC Filing (Aug 5, 2026)

This article reports on a TENET HEALTHCARE CORP (THC) SEC Form 144 filing from August 5, 2026. The filing indicates a proposed sale of 600 shares of common stock with an aggregate market value of $157,606.35, acquired through restricted stock vesting on May 23, …

SOPHiA GENETICS SA 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SOPH) 2026-08-05

SOPHiA GENETICS SA (NASDAQ:SOPH) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.20, which beat estimates by $0.02. The company also announced revenue of $23.31M, representing a 27.22% year-over-year increase and beating expectations by $1.60M. The slide deck was released in …